| Product Unit Size | Cost | Quantity | Stock |
|---|
Abexinostat is an inhibitor of histone deacetylase (HDAC). While it primarily targets HDAC1, it also shows activity against HDAC2, 3, 6, 8, and 10. Abexinostat has shown synergistic effect with bortezomib in lymphoma cells, inducing caspase-dependent apoptosis in vitro. It has exhibited efficacy when used in combination with doxorubicin against metastatic sarcoma.
| Cas No. | 783355-60-2 |
|---|---|
| Purity | ≥98% |
| Formula | C21H23N3O5 |
| Formula Wt. | 397.16 |
| IUPAC Name | 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide |
| Synonym | PCI-24781, CRA-024781, DRA-24781 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Bhalla S., Balasubramanian S., et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 15(10):3354-65 (2009). PMID: 19417023.
Choy E., Flamand Y., et al. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 121(8):1223-30 (2015). PMID: 25536954.